Open Access

Inhibitory effect of simvastatin in nasopharyngeal carcinoma cells

  • Authors:
    • Zhaoxin Ma
    • Weihua Wang
    • Yu Zhang
    • Min Yao
    • Liyun Ying
    • Liwei Zhu
  • View Affiliations

  • Published online on: April 23, 2019     https://doi.org/10.3892/etm.2019.7525
  • Pages: 4477-4484
  • Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nasopharyngeal carcinoma (NPC) is one of the most common malignant head and neck cancers in southern China. Although the local and regional control of NPC has been considerably improved, patients with advanced disease still suffer from poor prognosis. Statins inhibit the mevalonate pathway and play antiproliferative and proapoptotic roles in a number of cancer cells. However, the effects and molecular mechanism of statins in NPC treatment remain unclear. In this study, the cell viability of NPC cell line, C666‑1, after simvastatin exposure was determined using the alamarBlue Cell Viability Assay. Cell apoptosis in C666‑1 treated with simvastatin was assessed by flow cytometry and TUNEL assay. The expression levels of cell cycle regulatory proteins were determined using western blotting. Simvastatin markedly decreased cell viability in a concentration‑dependent manner, increased caspase 3 activity and induced apoptosis in C666‑1 cells. Simvastatin induced Bim expression by regulating phosphorylation of transcriptional factor c‑Jun. Simvastatin treatment induced cell cycle arrest in the G1 phase in C666‑1 cells by inhibiting the expression of cyclin D1 and cyclin‑dependent kinase 4, and enhancing p27 expression. Simvastatin treatment inhibited protein kinase B and extracellular signal regulated kinase 1/2 activation. In conclusion, the results of the present study reveal the possible molecular mechanism of simvastatin‑induced anti‑tumor effects in C666‑1 and suggest that simvastatin is a potential chemotherapy agent in NPC treatment.

References

1 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM and Chen WQ: Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer. 36:902017. View Article : Google Scholar : PubMed/NCBI

3 

Nor Hashim NA, Ramzi NH, Velapasamy S, Alex L, Chahil JK, Lye SH, Munretnam K, Haron MR and Ler LW: Identification of genetic and non-genetic risk factors for nasopharyngeal carcinoma in a Southeast Asian population. Asian Pac J Cancer Prev. 13:6005–6010. 2012. View Article : Google Scholar : PubMed/NCBI

4 

Chua DT, Sham JS, Kwong DL and Au GK: Treatment outcome after radiotherapy alone for patients with Stage I–II nasopharyngeal carcinoma. Cancer. 98:74–80. 2003. View Article : Google Scholar : PubMed/NCBI

5 

Yau TK, Lee AW, Wong DH, Pang ES, Ng WT, Yeung RM and Soong IS: Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: Impact of chemotherapy schemes. Int J Radiat Oncol Biol Phys. 66:1004–1010. 2006. View Article : Google Scholar : PubMed/NCBI

6 

Qiu S, Lin S, Tham IW, Pan J, Lu J and Lu JJ: Intensity-modulated radiation therapy in the salvage of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 83:676–683. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Chua MLK, Wee JTS, Hui EP and Chan ATC: Nasopharyngeal carcinoma. Lancet. 387:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI

8 

Ng WT, Lee MC, Hung WM, Choi CW, Lee KC, Chan OS and Lee AW: Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 79:420–428. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Ou X, Zhou X, Shi Q, Xing X, Yang Y, Xu T, Shen C, Wang X, He X, Kong L, et al: Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: New insight into the value of total dose of cisplatin and radiation boost. Oncotarget. 6:38381–38397. 2015. View Article : Google Scholar : PubMed/NCBI

10 

Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, Deng X, Huang S, Lin C and Lu T: Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: An analysis of survival and treatment toxicities. Radiother Oncol. 110:398–403. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Causevic-Ramosevac A and Semiz S: Drug interactions with statins. Acta Pharm. 63:277–293. 2013. View Article : Google Scholar : PubMed/NCBI

12 

Reiner Z: Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 24:1057–1066. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Duncan RE, El-Sohemy A and Archer MC: Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J Biol Chem. 279:33079–33084. 2004. View Article : Google Scholar : PubMed/NCBI

14 

Bockorny B and Dasanu CA: HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: What is the current evidence? Ann Hematol. 94:1–12. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Feldt M, Bjarnadottir O, Kimbung S, Jirström K, Bendahl PO, Veerla S, Grabau D, Hedenfalk I and Borgquist S: Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial. J Transl Med. 13:1332015. View Article : Google Scholar : PubMed/NCBI

16 

Takeda I, Maruya S, Shirasaki T, Mizukami H, Takahata T, Myers JN, Kakehata S, Yagihashi S and Shinkawa H: Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 98:890–899. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Koul HK, Koul S and Meacham RB: New role for an established drug? Bisphosphonates as potential anticancer agents. Prostate Cancer Prostatic Dis. 15:111–119. 2012. View Article : Google Scholar : PubMed/NCBI

18 

Warita K, Warita T, Beckwitt CH, Schurdak ME, Vazquez A, Wells A and Oltvai ZN: Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. Sci Rep. 4:75932014. View Article : Google Scholar : PubMed/NCBI

19 

Liu H, Liang SL, Kumar S, Weyman CM, Liu W and Zhou A: Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer Chemother Pharmacol. 63:997–1005. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Parikh A, Childress C, Deitrick K, Lin Q, Rukstalis D and Yang W: Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate. 70:971–981. 2010. View Article : Google Scholar : PubMed/NCBI

21 

Ogunwobi OO and Beales IL: Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol. 103:825–837. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Wang W, Le W, Cho DY, Hwang PH and Upadhyay D: Novel effects of statins in enhancing efficacy of chemotherapy in vitro in nasopharyngeal carcinoma. Int Forum Allergy Rhinol. 1:284–289. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Hiura TS, Li N, Kaplan R, Horwitz M, Seagrave JC and Nel AE: The role of a mitochondrial pathway in the induction of apoptosis by chemicals extracted from diesel exhaust particles. J Immunol. 165:2703–2711. 2000. View Article : Google Scholar : PubMed/NCBI

24 

Zhu BK, Wang P, Zhang XD, Jiang CC, Chen LH, Avery-Kiejda KA, Watts R and Hersey P: Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells. Anticancer Drugs. 19:189–200. 2008. View Article : Google Scholar : PubMed/NCBI

25 

Biswas SC, Shi Y, Sproul A and Greene LA: Pro-apoptotic Bim induction in response to nerve growth factor deprivation requires simultaneous activation of three different death signaling pathways. J Biol Chem. 282:29368–29374. 2007. View Article : Google Scholar : PubMed/NCBI

26 

Massague J: G1 cell-cycle control and cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI

27 

Musgrove EA, Lee CS, Buckley MF and Sutherland RL: Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA. 91:8022–8026. 1994. View Article : Google Scholar : PubMed/NCBI

28 

Grillo M, Bott MJ, Khandke N, McGinnis JP, Miranda M, Meyyappan M, Rosfjord EC and Rabindran SK: Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat. 95:185–194. 2006. View Article : Google Scholar : PubMed/NCBI

29 

Arber N, Doki Y, Han EK, Sgambato A, Zhou P, Kim NH, Delohery T, Klein MG, Holt PR and Weinstein IB: Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 57:1569–1574. 1997.PubMed/NCBI

30 

Wali VB, Bachawal SV and Sylvester PW: Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Exp Biol Med (Maywood). 234:639–650. 2009. View Article : Google Scholar : PubMed/NCBI

31 

Wali VB and Sylvester PW: Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids. 42:1113–1123. 2007. View Article : Google Scholar : PubMed/NCBI

32 

Torii S, Yamamoto T, Tsuchiya Y and Nishida E: ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci. 97:697–702. 2006. View Article : Google Scholar : PubMed/NCBI

33 

Liang J and Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2:339–345. 2003. View Article : Google Scholar : PubMed/NCBI

34 

Tran H, Brunet A, Griffith EC and Greenberg ME: The many forks in FOXO's road. Sci STKE. 2003:RE52003.PubMed/NCBI

35 

Reagan-Shaw S, Afaq F, Aziz MH and Ahmad N: Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin. Oncogene. 23:5151–5160. 2004. View Article : Google Scholar : PubMed/NCBI

36 

Subramaniam G, Campsteijn C and Thompson EM: Co-expressed Cyclin D variants cooperate to regulate proliferation of germline nuclei in a syncytium. Cell Cycle. 14:2129–2141. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ma, Z., Wang, W., Zhang, Y., Yao, M., Ying, L., & Zhu, L. (2019). Inhibitory effect of simvastatin in nasopharyngeal carcinoma cells. Experimental and Therapeutic Medicine, 17, 4477-4484. https://doi.org/10.3892/etm.2019.7525
MLA
Ma, Z., Wang, W., Zhang, Y., Yao, M., Ying, L., Zhu, L."Inhibitory effect of simvastatin in nasopharyngeal carcinoma cells". Experimental and Therapeutic Medicine 17.6 (2019): 4477-4484.
Chicago
Ma, Z., Wang, W., Zhang, Y., Yao, M., Ying, L., Zhu, L."Inhibitory effect of simvastatin in nasopharyngeal carcinoma cells". Experimental and Therapeutic Medicine 17, no. 6 (2019): 4477-4484. https://doi.org/10.3892/etm.2019.7525